Taiwan Biomaterial Co., Ltd. (6649.TWO)
- Previous Close
37.40 - Open
37.30 - Bid --
- Ask --
- Day's Range
36.40 - 38.05 - 52 Week Range
25.40 - 46.50 - Volume
105,464 - Avg. Volume
391,577 - Market Cap (intraday)
1.594B - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
48.65 - EPS (TTM)
0.78 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Aug 9, 2023
- 1y Target Est
--
Taiwan Biomaterial Co., Ltd. engages in the development and sale of medical devices in Taiwan. The company provides Foamagen, a foamy dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and the nickel-titanium guidewire for guiding cerebral vascular surgery; and tissue repair and regeneration products for the treatment of early osteoarthritis. Taiwan Biomaterial Co., Ltd. Was founded in 2010 and is based in Zhubei, Taiwan.
www.twbm.com.twRecent News: 6649.TWO
View MorePerformance Overview: 6649.TWO
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6649.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6649.TWO
View MoreValuation Measures
Market Cap
1.59B
Enterprise Value
1.31B
Trailing P/E
49.29
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.61
Price/Book (mrq)
2.42
Enterprise Value/Revenue
8.97
Enterprise Value/EBITDA
26.18
Financial Highlights
Profitability and Income Statement
Profit Margin
-13.02%
Return on Assets (ttm)
-1.43%
Return on Equity (ttm)
-1.73%
Revenue (ttm)
83.74M
Net Income Avi to Common (ttm)
-10.9M
Diluted EPS (ttm)
0.78
Balance Sheet and Cash Flow
Total Cash (mrq)
299.77M
Total Debt/Equity (mrq)
9.30%
Levered Free Cash Flow (ttm)
-10.69M